Our story

Founded in 2001, we are a clinical-stage biopharmaceutical company focused on delivering ground-breaking cancer therapeutics to patients globally.  

We leverage our deep expertise in oncology-focused novel therapeutics for the benefit of cancer patients everywhere

Our story

Founded in 2001, we are a clinical stage biotech company committed to the discovery and development of novel and effective therapeutics for the treatment of cancer.

We leverage our deep expertise in oncology focused novel therapeutics for the benefit of cancer patients everywhere.

Video of our Journey

Our approach

We focus on developing innovative therapeutics addressing several hallmarks of cancer, leveraging our deep capabilities in science and building value added collaborations with leading companies globally.

drug development

Our impact

We have built comprehensive drug discovery and development capabilities, nurtured a growing team of passionate scientists, and collaborated with partners from across the world.

Media center

Get the latest updates from Aurigene in the news, conferences, events, and more.

November 19, 2026

November 18-20, 2026, 38th EORTC-NCI-AACR Symposium 2026

September 30, 2026

₹1,600 Crore Approved for 41 Pharma & MedTech Innovation Projects under PRIP First Round

Get in touch with us:

Our publications

Explore our vast body of work in oncology research, innovative technology and therapeutics.

Novel HBS1L degraders identified from A-PROX and Directed Neosubstrate Degrader (DNsD) platforms for...

Phase 1 First-in-human study of AUR112, a highly selective MALT1 inhibitor, in relapsed...